Product
19 Interestana reports mention CRISPR, newest first. Each is summarised from the original reporting and links back to its publisher.
MIT Technology Review is gearing up to release its highly anticipated 2026 list of "Climate Tech Companies to Watch" on October 6th. This annual compilation, a cornerstone of the publication's commitment to tracking technological advancements, aims to spotlight ten companies…
A recent publication in the esteemed scientific journal Nature, dated September 28, 2026, introduces a new generation of genome editing technologies poised to significantly expand the scope of genetic manipulation.
A pioneering CRISPR-based therapy has demonstrated a remarkable ability to reduce "bad" cholesterol levels by approximately half in patients suffering from challenging lipid disorders, with these significant reductions persisting for a full year following a single administration.
Researchers have employed CRISPR gene editing technology to modify donor stem cells, creating a potential new strategy for treating aggressive blood cancers. This innovative approach focuses on removing the CD33 protein from these stem cells.
Anthropic announced that its artificial intelligence model, Claude, has autonomously discovered a new enzyme system. The company is comparing this discovery to the revolutionary gene-editing tool CRISPR, highlighting its potential significance in biological research and applications.
A novel CRISPR-based gene editing therapy has demonstrated the ability to significantly reduce cholesterol levels in participants for a duration of at least 12 months. The findings, published online on September 1, 2026, in the journal Nature, stem…
A significant scientific advancement has been achieved by researchers who have successfully employed a CRISPR-based technique to transform male mouse embryos into genetically female clones. This novel approach effectively removes the Y chromosome, resulting in female animals that are genetically…
Researchers have developed a novel in vivo model capable of recovering human T cells directly from solid tumors, a breakthrough that allows for genome-wide CRISPR screens to identify specific targets for improving CAR T cell antitumour activity.
Academic AI researchers are navigating a significant shift in the field, as the cutting edge of artificial intelligence research has largely moved from universities to private companies over the past four years.
Researchers have identified and engineered a novel CRISPR-associated enzyme capable of directly shredding the DNA of cancer cells, presenting a potentially groundbreaking new approach to cancer therapy. This enzyme, derived from bacteria, can be precisely directed to target tumor-causing mutations…
Scientists have successfully employed CRISPR gene-editing technology to enhance the efficacy of immunotherapy against prostate cancer in preclinical mouse models. This innovative approach targets specific genetic pathways within cancer cells, making them more visible and vulnerable to the body's own…
Researchers have utilized predictions from the AI model AlphaFold3 to enhance the specificity of CRISPR genome-editing enzymes. Published online on July 22, 2026, in Nature, the study details how AlphaFold3's accurate predictions of molecular contacts within CRISPR complexes have been…
Researchers have engineered novel CRISPR proteins using artificial intelligence that exhibit superior efficiency in genome editing compared to their naturally occurring counterparts. This advancement was detailed in a study published online in Nature on July 17, 2026.
Researchers have successfully designed novel CRISPR enzymes using artificial intelligence, creating "molecular scissors" with gene-editing capabilities not found in nature. This breakthrough, detailed in a publication on July 16, 2026, significantly expands the toolkit for genetic engineering.
Researchers have repurposed a bacterial self-destruct mechanism, utilizing CRISPR technology, to selectively eliminate diseased cells, including tumor cells in mouse models of cancer. This innovative approach, detailed in a publication on July 14, 2026, in Nature, leverages a DNA-shredding enzyme…
CRISPR technology is evolving beyond direct DNA editing to target the epigenome, offering a new frontier for treating genetic diseases. This approach focuses on modifying gene expression without altering the underlying DNA sequence, a development detailed in a recent publication…
Several start-up companies are advancing therapies that directly edit the epigenome to address a variety of diseases. These novel treatments aim to modify gene expression without altering the underlying DNA sequence, targeting specific epigenetic markers that contribute to illness.
Scientists utilized an advanced genome-editing tool in early human embryos to investigate the function of a key gene in early development, according to research published in Nature on Thursday. This next-generation CRISPR technology demonstrated enhanced precision and reduced damage compared…
Jennifer Doudna, a Nobel Prize-winning scientist and Professor at the University of California, Berkeley, discussed the origins of CRISPR gene editing technology and its future implications in an interview with Emily Chang for Bloomberg.